valoctocogene roxaparvovec

BioMarin Banks on More Robust Data in Hemophilia A Resubmission
BioSpace
Fri, 09/30/22 - 10:59 am
Biomarin
FDA
hemophilia A
valoctocogene roxaparvovec
BioMarin's hemophilia gene therapy Roctavian wins conditional EU backing amid FDA delay
Fierce Pharma
Mon, 06/27/22 - 10:05 am
Biomarin
Roctavian
EMA
FDA
hemophilia A
valoctocogene roxaparvovec
BioMarin Delays Hemophilia A Therapy Filing as FDA Calls for More Data
BioSpace
Tue, 05/31/22 - 11:57 pm
Biomarin
hemophilia A
FDA
valoctocogene roxaparvovec
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
Yahoo/Zacks.com
Tue, 03/9/21 - 10:37 am
Biomarin
gene therapy
hemophilia A
valoctocogene roxaparvovec
FDA
RMAT
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Sat, 07/25/20 - 02:25 pm
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Wed, 06/17/20 - 10:00 pm
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Mon, 06/1/20 - 10:42 am
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Thu, 12/12/19 - 10:52 am
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Fri, 08/2/19 - 10:37 am
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
Sun, 01/6/19 - 02:09 pm
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor